Extra-Anogenital Giant Cutaneous Squamous Cell Carcinomas
Extra-anogenital giant cSCCs are rare but have worse outcomes compared to smaller tumors. Prompted by limited data, the authors conducted a retrospective study to gather more information about giant cSCCs to optimize clinical care. We identified seven cases of giant cSCCs from a review of cSCC cases...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-03-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/3/421 |
| _version_ | 1797240308233142272 |
|---|---|
| author | Mateusz K. Mateuszczyk Iwona Chlebicka Magdalena Łyko Joanna Maj Jacek C. Szepietowski |
| author_facet | Mateusz K. Mateuszczyk Iwona Chlebicka Magdalena Łyko Joanna Maj Jacek C. Szepietowski |
| author_sort | Mateusz K. Mateuszczyk |
| collection | DOAJ |
| description | Extra-anogenital giant cSCCs are rare but have worse outcomes compared to smaller tumors. Prompted by limited data, the authors conducted a retrospective study to gather more information about giant cSCCs to optimize clinical care. We identified seven cases of giant cSCCs from a review of cSCC cases treated in the Unit of Dermatosurgery between 2016 and 2022. Most patients were male (85.71%) with a mean age of 80.29 ± 12.22 years. UV radiation was the most common risk factor (five cases) followed by smoking (three cases) and hidradenitis suppurativa (one case). Most giant cases were located in the head area (71.4%) and the diameter of lesions ranged from 6 to 18 cm. All patients corresponded to tumor stage T3, and 42.86% of patients had lymph node metastases. Surgical excision was the treatment of choice in most cases (85.71%), while a combination of cemiplimab and RP1 was used in some cases due to the ineffectiveness of treatment or contraindications to other therapies. The authors emphasize the importance of early detection and prevention of modifiable risk factors, such as UV radiation, and a multidisciplinary approach to treatment. Other therapies, including immunotherapy, may become increasingly important. |
| first_indexed | 2024-04-24T18:05:22Z |
| format | Article |
| id | doaj.art-eadadb2686624bfdae95bc990fc35325 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-04-24T18:05:22Z |
| publishDate | 2024-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-eadadb2686624bfdae95bc990fc353252024-03-27T13:51:25ZengMDPI AGLife2075-17292024-03-0114342110.3390/life14030421Extra-Anogenital Giant Cutaneous Squamous Cell CarcinomasMateusz K. Mateuszczyk0Iwona Chlebicka1Magdalena Łyko2Joanna Maj3Jacek C. Szepietowski4Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, PolandDepartment of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, PolandDepartment of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, PolandDepartment of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, PolandDepartment of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, PolandExtra-anogenital giant cSCCs are rare but have worse outcomes compared to smaller tumors. Prompted by limited data, the authors conducted a retrospective study to gather more information about giant cSCCs to optimize clinical care. We identified seven cases of giant cSCCs from a review of cSCC cases treated in the Unit of Dermatosurgery between 2016 and 2022. Most patients were male (85.71%) with a mean age of 80.29 ± 12.22 years. UV radiation was the most common risk factor (five cases) followed by smoking (three cases) and hidradenitis suppurativa (one case). Most giant cases were located in the head area (71.4%) and the diameter of lesions ranged from 6 to 18 cm. All patients corresponded to tumor stage T3, and 42.86% of patients had lymph node metastases. Surgical excision was the treatment of choice in most cases (85.71%), while a combination of cemiplimab and RP1 was used in some cases due to the ineffectiveness of treatment or contraindications to other therapies. The authors emphasize the importance of early detection and prevention of modifiable risk factors, such as UV radiation, and a multidisciplinary approach to treatment. Other therapies, including immunotherapy, may become increasingly important.https://www.mdpi.com/2075-1729/14/3/421giant cutaneous squamous cell carcinomacutaneous squamous cell carcinomasquamous cell carcinoma |
| spellingShingle | Mateusz K. Mateuszczyk Iwona Chlebicka Magdalena Łyko Joanna Maj Jacek C. Szepietowski Extra-Anogenital Giant Cutaneous Squamous Cell Carcinomas Life giant cutaneous squamous cell carcinoma cutaneous squamous cell carcinoma squamous cell carcinoma |
| title | Extra-Anogenital Giant Cutaneous Squamous Cell Carcinomas |
| title_full | Extra-Anogenital Giant Cutaneous Squamous Cell Carcinomas |
| title_fullStr | Extra-Anogenital Giant Cutaneous Squamous Cell Carcinomas |
| title_full_unstemmed | Extra-Anogenital Giant Cutaneous Squamous Cell Carcinomas |
| title_short | Extra-Anogenital Giant Cutaneous Squamous Cell Carcinomas |
| title_sort | extra anogenital giant cutaneous squamous cell carcinomas |
| topic | giant cutaneous squamous cell carcinoma cutaneous squamous cell carcinoma squamous cell carcinoma |
| url | https://www.mdpi.com/2075-1729/14/3/421 |
| work_keys_str_mv | AT mateuszkmateuszczyk extraanogenitalgiantcutaneoussquamouscellcarcinomas AT iwonachlebicka extraanogenitalgiantcutaneoussquamouscellcarcinomas AT magdalenałyko extraanogenitalgiantcutaneoussquamouscellcarcinomas AT joannamaj extraanogenitalgiantcutaneoussquamouscellcarcinomas AT jacekcszepietowski extraanogenitalgiantcutaneoussquamouscellcarcinomas |